Dom SommaNever seen a conference where they don't provide coffee to non-clinicians...we are human beings! 🤣🤣
#Eular #Eular2025 @eular.org
IQWiG#CDAI is the first choice for measuring treatment effects of disease-modifying #antirheumatic drugs. Using a broad evidence base, a team of IQWiG authors compared measurement tools.
Article in #BMCRheumatology: https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-022-00314-7
As we are still missing big chunks of our #EvidenceBasedMedicine community from the birdsite, boosts are much appreciated!
Also: Do you know people, journals and institutions to follow on topics like this?
A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis - BMC Rheumatology
Background Some composite measures for determining the treatment effects of disease-modifying antirheumatic drugs on remission and low disease activity (LDA) in rheumatoid arthritis (RA) may produce misleading results if they include an acute phase reactant (APR). To inform the choice of appropriate measure, we performed a systematic comparison of treatment effects using different composite measures. Methods We used data generated for a systematic review of biologics in RA conducted by the Institute for Quality and Efficiency in Health Care and data from systematic reviews of newer biologics and Janus kinase (JAK) inhibitors provided by sponsors. The studies included had been conducted up to 2020 and investigated comparisons of biologics with placebo and head-to-head comparisons of biologics. Treatment effects on LDA and remission in studies investigating biologics or JAK inhibitors in RA were compared among 4 composite measures: the disease activity score 28 (DAS 28), the simplified disease activity index (SDAI), the Boolean approach (remission only), and the clinical disease activity index (CDAI)—only the latter does not include an APR. Results 49 placebo-controlled studies included 9 different biologics; 48 studies (16,233 patients) investigated LDA and 49 (16,338 patients) investigated remission. 11 active-controlled studies (5996 patients) investigated both LDA and remission and included 5 different head-to-head comparisons of biologics and 5 different comparisons (6 studies) of biologics with JAK inhibitors. Statistically significantly larger treatment effects were found for biologics or JAK inhibitors versus placebo or active control in 16% of pairwise comparisons of composite measures (27 of 168). Most of these larger effects were observed for composite measures with an APR, i.e. the DAS 28 (19 comparisons) followed by the SDAI (n = 7). Larger effects were most frequently detected in favour of interleukin (IL)-6 inhibitors and to a lesser extent for JAK inhibitors versus treatments with different modes of action. Conclusions The use of the DAS 28 and SDAI in clinical studies may generate results favouring certain treatments based on their mode of action (e.g. IL-6 inhibitors versus other biologics). To enable unbiased comparative effectiveness research, a composite measure without an APR (i.e. the CDAI) should thus be the measure of choice.
Der Clinical Disease Activity Index - kurz #CDAI - ist zur Messung von Behandlungseffekten ist bei krankheitsmodifizierenden #Antirheumatika erste Wahl. Denn andere Messinstrumente wie #SDAI und #DAS28 können die Effekte überschätzen.
Ein Team um IQWiG-Autorinnen hat die verfügbaren Messinstrumente auf einer breite Datenbasis verglichen.
Zur Meldung (12'22): https://www.iqwig.de/presse/pressemitteilungen/pressemitteilungen-detailseite_84103.html
Zur Publikation: https://bmcrheumatol.biomedcentral.com/articles/10.1186/s41927-022-00314-7
Clinical Disease Activity Index (CDAI) bei Bewertung von Behandlungseffekten erste Wahl
Team um IQWiG-Autorinnen vergleicht Instrumente zur Messung von Behandlungseffekten bei krankheitsmodifizierenden Antirheumatika systematisch auf einer breiten Datenbasis.
EU-OSHA 🇪🇺RT @eular_org: 🌍 Today is the International Day of Persons with Disabilities!
📢 2022 theme: 'Not All Disabilities are Visible’
Help raise awareness about the impact of diseases like mental health disorders, chronic pain & fatigue!
#InternationalDayOfPeopleWithDisability #EULAR #Awarenessday
🐦🔗: https://n.respublicae.eu/EU_OSHA/status/1599009152474324992
RT @eular_org: Happening today!
Hear you later🙂
#WorldArthritisDay #WorldArthritisDay2022 #WAD #WAD22 #EULAR #eularHPR #eularPARE